Marksans Pharma Ltd. on Wednesday, November 19, said its wholly-owned subsidiary received final approval from the US drug regulator for an anti-diarrheal medication.

The company, in an exchange filing, said its wholly-owned subsidiary, Marksans Pharma Inc's Abbreviated New Drug Application received the final approval from the US Food and Drug Administration (USFDA) for the over-the-counter Loperamide Hydrochloride Tablets USP, 2 mg.

The same is a generic drug, "bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC," the company said.

Marksans Pharma added that the Loperamide Hydrochloride tablet is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.

Earlier this week, the company's fully owned UK subsidiary,

See Full Page